PROTACs to address the challenges facing small molecule inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Molecular Biology

Background:

• Small molecule protein inhibitors are vital medicines and research tools.
• Advances in omics technologies accelerate the discovery of disease-relevant proteins.
• Traditional inhibitors face challenges like selectivity, resistance, and targeting 'undruggable' proteins.

Purpose of the Study:

• To review recent advances in PROteolysis TArgeting Chimera (PROTAC) design.
• To discuss how PROTACs address challenges posed by traditional small molecule inhibitors.
• To explore the potential of PROTACs for next-generation therapeutics and chemical biology tools.

Main Methods:

• PROTACs are heterobifunctional molecules that recruit E3 ligases to target proteins.
• PROTACs induce polyubiquitination, leading to proteasomal degradation of the target protein.
• This review analyzes recent PROTAC design strategies and their efficacy.

Main Results:

• PROTACs offer a catalytic mechanism for complete target protein degradation, unlike traditional inhibitors.
• PROTACs demonstrate potential in overcoming drug selectivity and resistance issues.
• PROTACs can target proteins previously considered undruggable, including multi-domain proteins.

Conclusions:

• PROTAC technology presents a promising avenue for developing highly selective and effective medicines.
• Further research into PROTAC limitations will enhance their therapeutic potential.
• PROTACs represent a significant advancement in chemical biology and drug discovery.